TrialJAMA dermatology2025

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.

April W Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.